

RESPONSE TO QUESTIONS

1. **Question:** *“If we are able to find a better price for Naloxone kits from a different provider can we use the grant funds to purchase the kits through them instead?”*

Response: In Section 2.2 *Detailed Scope of Work and Additional Requirements*, it indicates that only FDA approved ready-to-use intranasal devices can be purchased through this RFP. NARCAN® Nasal Spray 4mg is the only FDA approved ready-to-use intranasal device. If this can be purchased from a different provider, you may choose to do so.

2. **Question:** *“The RFP indicates that 15% of the award can go towards Naloxone Training. Can you explain in more detail what is meant by training? For example, are we responsible to line up our own training or do you provide that? If you do provide the training, what all is included in it and how many people can attend? Would the training include a grantee attending training in SLC? Would that grantee then be able to go back and give that training to others – kind of like a training of trainers?”*

Response: According to the Opiate Overdose Response Act 26-55-107 (7)(b)(ii) no more than 15% of the total amount granted by the program is used to pay for grantees’ costs of providing training on the proper administration of an opiate antagonist in response to an opiate-related drug overdose event. According to the Opiate Overdose Response Act 26-55-106 (2)(a) when furnishing an opiate antagonist an overdose outreach provider:

(a) *Shall also furnish to the recipient of the opiate antagonist:*

- (i) *The written instruction under Subsection 26-55-104(3) received by the overdose outreach provider from the health care provider at the time the opiate antagonist was dispensed to the overdose outreach provider; or*
- (ii) *If the opiate antagonist was dispensed to the overdose outreach provider by a pharmacist or pharmacy intern, any written patient counseling under Section 58-17b-613 received by the overdose outreach provider at the time of dispensing; and*

(b) *May provide additional instruction on how to recognize and respond appropriately to an opiate-related drug overdose event.*

- The 15% would include the time it takes for the grantee to provide training to the recipient on the proper administration of an opiate antagonist.
- Train the Trainer trainings are being developed and dates will be released as soon as they are finalized.

3. **Question:** *“The Cover Page requests “**Contract Person**”. Do you mean the person to be the point of contact: the Contact person, or do you want the contract manager or other legal liaison? Our guess is it is a typo and you want our contact person. Either way we will comply.”*

Response: Yes, this is a typo. It is the point of contact-the form is updated on the link with the correction.